Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates. Key Financial Results: Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million; Annual revenue of $185.7 million, Net loss of.

Maravai LifeSciences Reports Third Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates. Quarterly Results: Revenue of $41.6 million, Net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million “We exited the third quarter confident about the future of our business. Cygnus co.

MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders

Allegedly, Maravai misstated revenue and overstated goodwill due to weak internal controls, causing a 22% stock drop after delaying its earnings report.

Maravai LifeSciences Reports Second Quarter 2025 Financial Results

Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings